Curcuminoids inhibit EV-D68 infection by targeting the CRYAB-RBM26 axis to counteract virus-induced hijacking of nucleic acid metabolism

This study focuses on the current situation where there is a lack of effective antiviral therapies and approved vaccines for enterovirus D68 (EV-D68). With this virus as the core research object, a systematic investigation will be carried out.At the animal and cellular levels, the study will evaluate the differential characteristics of curcumin (CUR) and demethoxycurcumin (DMC) in resisting EV-D68 infection, conduct in-depth analysis of the physicochemical properties of the two substances and their differences at the cellular level, so as to clarify their basic properties in vitro and their effects on cells.Meanwhile, by identifying the hub targets of the antiviral pathways mediated by CUR and DMC, and combining technical methods such as proteomics, molecular docking, and metabolomics, the study will screen the protein libraries regulated by these hub targets, analyze the similarities and differences in the metabolic microenvironments regulated by the two substances, and further construct a drug-target-metabolic pathway molecular network.On this basis, the mechanism of action of curcuminoids on nucleic acid metabolism in virus infection models will be clarified, and finally the common antiviral mechanisms of CUR and DMC will be analyzed. This research can not only provide an important basis for the clinical application of curcuminoids but also fill the gap in the research field of host targets of natural products against enteroviruses.